Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 30:2022:7137357.
doi: 10.1155/2022/7137357. eCollection 2022.

Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB

Jia Chen  1 , Sheng Wei  1 , Tianye Zhao  2 , Xunlei Zhang  1 , Yilang Wang  1 , Xiaodong Zhang  1
Affiliations

Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB

Jia Chen et al. Dis Markers. .

Abstract

Background: To assess the prognostic value of pretreatment serum biomarkers in stage IV non-small-cell lung cancer (NSCLC) patients treated with PD-1 (programmed cell death protein 1) inhibitors and their value as a predictor of benefit.

Methods: We performed a retrospective study including patients with stage IV NSCLC who were treated with anti-PD-1 drugs in first or advanced lines of therapy in the Affiliated Tumor Hospital of Nantong University. Serum biomarkers such as NLR, dNLR, LMR, PAB, ALB, and LIPI scores were calculated and analyzed in detail.

Results: A total of 85 patients with stage IV NSCLC treated with PD-1 inhibitors in the first or advanced lines of therapy were included in this subject. According to the tumor response of PD-1-based treatment, ORR was 42.4% (36/85) and DCR was 68.2% (58/85). The median OS and PFS were 20.0 months and 7.0 months, respectively. The ROC curves showed that the serum biomarkers of NLR, dNLR, LDH, LMR, PAB, and ALB were significantly associated with overall survival and helped to determine the cut-off value. The multivariate Cox proportional hazard analyses for stage IV NSCLC patients treated with PD-1 inhibitors indicated that dNLR (P < 0.001) and ALB (P = 0.033) were independent prognostic indicators of PFS, while liver metastasis (P = 0.01), NLR (P = 0.01), dNLR (P = 0.001), and LMR (P = 0.006) were independent prognostic indicators of OS. Moreover, patients of the good LIPI group showed prolonged PFS and OS than those with intermediate/poor LIPI score (P < 0.001 and P = 0.006, respectively).

Conclusions: Pretreatment dNLR is an independent prognostic indicator of both PFS and OS in stage IV NSCLC patients treated with PD-1 inhibitors. Pretreatment LIPI, combining dNLR > 3 and LDH>ULN, was correlated with worse outcome for stage IV NSCLC patients treated with ICI. High NLR, high dNLR, low LMR, and low ALB at baseline might be useful as an early predictive biomarker of benefit.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
ROC of NLR, dNLR, LDH, LMR, PAB, and ALB.
Figure 2
Figure 2
Kaplan-Meier curves of PFS in stage IV non-small-cell lung cancer treated with PD-1 inhibitors.
Figure 3
Figure 3
Kaplan-Meier curves of OS in stage IV non-small-cell lung cancer treated with PD-1 inhibitors.
Figure 4
Figure 4
Kaplan-Meier curves of PFS in stage IV NSCLC treated with PD-1 inhibitor monotherapy.
Figure 5
Figure 5
Kaplan-Meier curves of OS in stage IV NSCLC treated with PD-1 inhibitor monotherapy.
Figure 6
Figure 6
Kaplan-Meier curves of PFS in stage IV NSCLC treated with PD-1 inhibitor combination therapy.
Figure 7
Figure 7
Kaplan-Meier curves of OS in stage IV NSCLC treated with PD-1 inhibitor combination therapy.
Figure 8
Figure 8
Multifactor model of LIPI score for survival outcome of stage IV NSCLC patients treated with PD-1 inhibitors.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians . 2018;68(6):394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Siegel R. L., Miller K. D., Fuchs H. E., Jemal A. Cancer statistics, 2021. CA: a Cancer Journal for Clinicians . 2021;71(1):7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Arbour K. C., Riely G. J. Systemic therapy for locally advanced and metastatic non-small cell lung Cancer. JAMA . 2019;322(8):764–774. doi: 10.1001/jama.2019.11058. - DOI - PubMed
    1. Relli V., Trerotola M., Guerra E., Alberti S. Abandoning the notion of non-small cell lung cancer. Trends in Molecular Medicine . 2019;25(7):585–594. doi: 10.1016/j.molmed.2019.04.012. - DOI - PubMed
    1. Camidge D. R., Doebele R. C., Kerr K. M. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nature Reviews. Clinical Oncology . 2019;16(6):341–355. doi: 10.1038/s41571-019-0173-9. - DOI - PubMed

MeSH terms